Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | ERAS-601 |
| Synonyms | |
| Therapy Description |
ERAS-601 inhibits SHP2, potentially resulting in decreased cell growth and inhibition of tumor growth (Cancer Res 2022;82(12_Suppl):Abstract nr 2669). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| ERAS-601 | ERAS 601|ERAS601 | SHP2 Inhibitor 20 | ERAS-601 inhibits SHP2, potentially resulting in decreased cell growth and inhibition of tumor growth (Cancer Res 2022;82(12_Suppl):Abstract nr 2669). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT04670679 | Phase I | ERAS-601 | FLAGSHP-1: A Dose Escalation/Expansion Study of ERAS-601 in Patients With Advanced or Metastatic Solid Tumors | Active, not recruiting | USA | AUS | 0 |
| NCT06957327 | Phase Ib/II | ERAS-601 | A Study of ERAS-601 in People With Chordoma | Recruiting | USA | 0 |